Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Woman holding a baby © Arne Hoel, World Bank

Malaria in pregnancy has devastating consequences for both mother and fetus, requiring prompt and effective treatment. The risk of infection is highest in the first trimester when many pregnancies are yet to be protected by chemoprevention with intermittent preventive treatment (IPTp) which begins in the second trimester. Up until now, artemisinin-based combination therapies (ACTs) were recommended by the WHO as first-line treatment in all patient groups, except in first-trimester women, for whom quinine with clindamycin has been recommended due to concerns about the potential embryotoxicity of artemisinins.

Although there is limited data on specific artemisinin-based combination therapies (ACTs) other than artemether-lumefantrine, the other ACTs (including artesunate-amodiaquine, artesunate-mefloquine and dihydroartemisinin-piperaquine but not artesunate–sulfadoxine–pyrimethamine) may be considered for use where artemether-lumefantrine is not available, given the demonstrated poorer outcomes of quinine treatment, along with the challenges of adherence to a seven-day course of treatment. 

ACTs are already recommended for treatment in second and third trimesters. This study, the largest of its kind, was a collaborative effort between over 20 research groups with data from over 34,000 pregnancies from 12 cohort studies in ten countries collected over more than 20 years.

The meta-analysis results suggest that first-trimester treatment with artemisinin-based treatment is as safe and possibly more effective than non-artemisinin-based treatments, including quinine-based regimens. Importantly, artemether-lumefantrine, the ACT with the most safety data, was associated with 42% fewer adverse pregnancy outcomes (pregnancy loss or major congenital malformations) than oral quinine in the first trimester.

Dr Makoto Saito, Assistant Professor at The Institute of Medical Science, The University of Tokyo and part of the WorldWide Antimalarial Research Network, said: “At WWARN, we have previously shown that ACTs have a superior efficacy and much better tolerability and lower transmission risk after treatment than quinine. This new study provides an update on a previous study, confirming the evidence on safety in the first trimester using all the currently available clinical data.

“This study provides strong evidence to policy makers that ACTs should replace quinine-based regimens as the preferred treatment for uncomplicated falciparum malaria for everybody, including pregnant women in their first trimester.”

The full story is available on the WWARN website.

Read the publications 'Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis' on The Lancet website.

Similar stories

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

SMRU and BHF inaugurate new Admin Building

Today saw the long-awaited grand opening of the new Shoklo Malaria Research Unit (SMRU) / Borderland Health Foundation (BHF) Admin Building in Mae Ramat, Thailand, near the Thai-Myanmar border. And, boy was it worth the wait! Years in the planning, the very impressive new Admin Building looked absolutely stunning, the siting and architecture being universally admired by the many guests.

Study shows clear link between antibiotic treatment and acquisition of AMR bacteria in children

A study of the genetic diversity of Streptococcus pneumoniae, the bacterium responsible for hundreds of thousands of infant deaths each year, found that deep sequencing whole pneumococcal populations gave unsurpassed sensitivity for detecting multiple colonisations and was twice as effective at detecting invasive virulent strains of the bacteria as current best methods, say researchers in a study published in Nature Microbiology.

INTERBIO-21st study findings could help predict infants at risk of obesity

Fetal abdomen growth and the mother’s blood fat metabolites very early in pregnancy influence a child’s weight, body fat, vision and neurodevelopment at 2 years of age

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.